

Katherine C Verbist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4076842/publications.pdf>

Version: 2024-02-01

19
papers

1,733
citations

687363

13
h-index

940533

16
g-index

19
all docs

19
docs citations

19
times ranked

3377
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular basis of <i>ETV6</i> -mediated predisposition to childhood acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 364-373.	1.4	37
2	Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. <i>Frontiers in Pharmacology</i> , 2021, 12, 650295.	3.5	23
3	Synergistic Signaling of TLR and IFN β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 526-539.	5.6	38
4	Expansion and CD2/CD3/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity. <i>Cytotherapy</i> , 2020, 22, 276-290.	0.7	7
5	JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. <i>Blood</i> , 2020, 136, 657-668.	1.4	50
6	Translationally Relevant Oral Ruxolitinib Dosing Reduces Inflammation and Ameliorates Disease in Murine Models of Hemophagocytic Lymphohistiocytosis. <i>Blood</i> , 2020, 136, 21-21.	1.4	0
7	Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2019, 134, 147-159.	1.4	99
8	The Combination of Dexamethasone and Ruxolitinib Synergistically Attenuates Disease Manifestations in a Preclinical Model of Hemophagocytic Lymphohistiocytosis. <i>Blood</i> , 2019, 134, 81-81.	1.4	1
9	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 33, 937-948.e8.	16.8	142
10	Therapeutic Candidate Alpn-101, a Dual ICOS/CD28 Antagonist, Potently Suppresses Human/NSG Mouse Xenograft Graft Vs. Host Disease (GvHD) in a Dose Ranging Study and Reduces Disease Activity in a Mouse Model of Hemophagocytic Lymphohistiocytosis (HLH). <i>Blood</i> , 2018, 132, 2037-2037.	1.4	0
11	Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. <i>Nature</i> , 2016, 532, 389-393.	27.8	235
12	Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2016, 127, 1666-1675.	1.4	207
13	RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus. <i>Cell Host and Microbe</i> , 2016, 20, 13-24.	11.0	299
14	Apoptosis-Inducing-Factor-Dependent Mitochondrial Function Is Required for T Cell but Not B Cell Function. <i>Immunity</i> , 2016, 44, 88-102.	14.3	69
15	Inhibition of diacylglycerol kinase β restores restimulation-induced cell death and reduces immunopathology in XLP-1. <i>Science Translational Medicine</i> , 2016, 8, 321ra7.	12.4	41
16	Germline Genetic Variation in IKZF1 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, LBA-2-LBA-2.	1.4	3
17	Combined Treatment with Ruxolitinib and Dexamethasone Curtails Inflammation and Lessens Disease in Preclinical Studies of Hemophagocytic Lymphohistiocytosis. <i>Blood</i> , 2016, 128, 4894-4894.	1.4	1
18	RIPK1 Blocks Early Postnatal Lethality Mediated by Caspase-8 and RIPK3. <i>Cell</i> , 2014, 157, 1189-1202.	28.9	452

#	ARTICLE	IF	CITATIONS
19	T cell metabolism and the immune response. <i>Seminars in Immunology</i> , 2012, 24, 399-404.	5.6	29